Full text loading...
薬理と治療
Abstract
Objective The aim of this study was to examine the efficacy and safety of caffeine treatment for premature infants who have apnea attacks according to the blood caffeine concentration. Methods Blood was collected before the administration of caffeine, and on days 1, 5 and 10 of caffeine administration. Using collected blood, blood caffeine concentrations were measured by an LC-MS/MS analysis. Regarding gestational age, birth weight, corrected age╱body weight╱days after birth at the start of the administration, and Apgar scores at 1 and 5 minutes, blood caffeine concentrations were compared between two groups. In addition, we investigated the relationship between the blood caffeine concentration and the improvement of apnea attacks, or adverse events. Results There were no significant differences in the blood caffeine concentrations for any of the items in the seven items listed above. The investigation of the improvement of apnea attacks revealed that the blood caffeine concentrations were significantly lower in the improved group, the total molecular concentrations, including caffeine metabolites, were also significantly lower than in the unimproved group. In addition, the blood caffeine concentration in one patient with a suspected adverse event caused by caffeine was within the therapeutic range. Conclusions It was suggested that the effect of caffeine is more likely to be obtained when the degree of growth is larger and the administration is started earlier. Moreover, we found that the more developed infants may have faster metabolism and excretion.
Data & Media loading...